Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis

BACKGROUND: Aflibercept is a relatively new anti-VEGF used to treat neovascular age-related macular degeneration (AMD). The purpose of this review is to evaluate the effect of pro re nata (PRN) and fixed regimen (bimonthly) of aflibercept injection for neovascular AMD on visual outcomes at 12 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Victor, Andi Arus, Putri, Yan Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503225/
https://www.ncbi.nlm.nih.gov/pubmed/36138445
http://dx.doi.org/10.1186/s40942-022-00416-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503225/
https://www.ncbi.nlm.nih.gov/pubmed/36138445
http://dx.doi.org/10.1186/s40942-022-00416-x

Ejemplares similares